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ABSTRACT
Introduction: The prevalence of trachomatous inflammation – follicular (TF) in 1–9-year-olds and of 
trachomatous trichiasis (TT) in ≥15-year-olds in four endemic evaluation units (EUs) of Darfur region, 
Sudan, was measured more than a year after the required single round of antibiotic mass drug 
administration (MDA).
Methods: Surveys were conducted using highly standardised, World Health Organization- 
recommended methodologies. Individuals aged ≥1 year, resident in selected households, were 
chosen for the survey using a two-stage cluster sampling process. Consenting adults and children 
were examined for the signs TF and TT by graders trained to international standards. Prevalence of 
disease in key indicator groups was calculated and weighted to the underlying population 
structure.
Results: A mean of 1,415 (range: 1,253–1,611) children aged 1–9 years were examined in each EU. 
The age-adjusted prevalence of TF in 1–9-year-olds in each of the four surveyed EUs was <5%. 
A mean of 1,139 people aged ≥15 years (range: 1,080–1,201) were examined in each EU. The 
estimated age- and gender-adjusted prevalence of TT in ≥15-year-olds was <0.2% in all four EUs. In 
general, the proportion of households with access to improved WASH facilities was generally lower 
in this study than in corresponding baseline studies.
Conclusions: No further MDA should be conducted in these four EUs for the next 2 years, at which 
point they should be re-surveyed to determine whether the prevalence of TF in 1–9-year-olds has 
remained <5%. Active TT case-finding is also not indicated. Environmental improvement and 
promotion of facial cleanliness measures should continue to be implemented to prevent disease 
recrudescence.
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Introduction
Trachoma is the world’s leading infectious cause of 
blindness.1 It is caused by an ocular Chlamydia tracho-
matis infection, presenting initially as a chronic inflam-
mation of the eyelid (which may be sufficiently florid to 
qualify, in the World Health Organization (WHO) sim-
plified grading system, as trachomatous inflammation— 
follicular [TF] and/or trachomatous inflammation— 
intense [TI]2). Recurrent infections and inflammation3 
can lead to trachomatous trichiasis (TT), an in-turning 
of the eyelashes that brings them into direct contact with 
the eyeball. TT causes intense pain and can lead to 
scarring of the cornea and, ultimately, blindness. 
Visual impairment from trachoma dramatically reduces 
an individual’s ability to make essential contributions to 
the family, such as supporting food production, collect-
ing water or caring for children. Furthermore, those 
blinded from trachoma require support from other 
members of the household, so the role of the carer in 
the household is also impacted. Trachoma is strongly 
associated with and propagates poverty,4 with grave 
medical, economic and social ramifications.
The Sudan National Trachoma Control Programme 
is making great progress towards the elimination of 
trachoma as a public health problem. The national 
plan was updated by the Trachoma Task Force in 2005 
to adopt the WHO-recommended SAFE (surgery, anti-
biotics, facial cleanliness, and environmental improve-
ment) strategy. The initial priority of the programme 
was to map trachoma in all states of Sudan by conduct-
ing population-based trachoma prevalence surveys dur-
ing 2006–2015 to facilitate planning. The deployed 
surveys were designed to estimate two key indicators of 
trachoma burden, namely TF prevalence among 
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children aged 1–9 years and TT prevalence among 
adults aged ≥15 years, in accordance with WHO indica-
tors for validating trachoma as a public health problem.5 
From this mapping, approximately 17% of Sudan’s 
population were identified to be living in areas endemic 
to trachoma. The prevalence of TF in children aged 1– 
9 years was as high as 17% and TT in adults aged 
≥15 years as high as 3.8%,6,7 well in excess of the thresh-
olds at which implementation of the SAFE strategy is 
recommended.
Sudan continues to face challenges in managing tra-
choma. For example, some endemic areas are insecure, 
or inaccessible during the rainy season; these issues 
hinder service provision. Despite this, in several dis-
tricts, annual mass drug administration (MDA) of azi-
thromycin, an effective antibiotic8 donated by Pfizer 
through the International Trachoma Initiative for tra-
choma elimination purposes, has been delivered in-line 
with international recommendations. (Individuals in 
treated districts who did not qualify for azithromycin 
were instead offered treatment with topical tetracycline 
eye ointment.) This involves one MDA round where the 
TF prevalence in 1–9-year-olds is 5.0–9.9%, and three 
annual rounds where the TF prevalence is 10.0–29.9%.9 
At the national level, the programme conducted 91 TT 
surgical camps, funded by The Carter Center and 
Sightsavers, between 2011 and 2018. Additional TT sur-
geries have also been carried out at state hospitals and 
alongside cataract surgical outreach campaigns. 
Trachoma health education programmes have also 
been implemented at community and school levels in 
targeted localities nationwide (Darfur was not among 
the targeted localities for these activities). This commu-
nity health education programme identifies community 
leaders, teachers, and midwives as focal persons who are 
subsequently trained in community participation for 
trachoma elimination work at the community level. 
The focal person then hosts regular health education 
sessions and group discussions about trachoma and the 
SAFE strategy. The focal person will also encourage 
community members to conduct environmental clean-
ing campaigns at villages and schools. School health 
education programmes have also been expanded to 
include trachoma curricula into basic and secondary 
schools in all targeted localities. At least one teacher is 
trained per school to carry out trachoma health educa-
tion in their school. Trachoma Friendship Societies have 
been developed to promote health education activities at 
both the community and school levels, though Darfur 
region was not included in these activities due to 
security challenges. It is nevertheless expected that, 
with proper planning, financial support, and dedication, 
Sudan can still reach the goal of eliminating trachoma as 
a public health problem.
The aim of the survey series presented in this manu-
script was to measure the prevalence of TF and TT in 
four localities of the Darfur region, namely Dar El Salam, 
Kalmindo, El Salam, and Belail. In these localities, the 
prevalence of TT was 0.0–0.6% and of TF was 5.0–9.9% 
during baseline mapping in 2014–56 and they duly 
received a single round of MDA between February and 
May 2017. Darfur-focussed S, F, and E interventions have 
not yet begun. The Trachoma Impact Survey (TIS) data 
generated in this exercise will enable the Sudan National 
Trachoma Programme to review progress towards elim-
ination in these localities and determine whether further 
interventions may be needed there in the future.
Methods
Study ethics
The study was approved by the Health Research Council 
in Sudan and the National Research Ethics Review 
Committee of the Sudan Federal Ministry of Health. 
The London School of Hygiene & Tropical Medicine 
Ethics Committee provided approval for Tropical Data 
to support trachoma surveys (16105).
Communities were contacted in advance of the 
team’s arrival. Eligible residents were given information 
about the study in the local language prior to enrolment. 
Those aged ≥15 years consented verbally for themselves; 
a parent or guardian consented verbally on behalf of 
those aged <15 years. Consent for examination was 
recorded in the Tropical Data app used for data collec-
tion. Identified active (inflammatory) trachoma was 
treated with tetracycline eye ointment, and individuals 
with significant ocular pathology, including TT, were 
referred to local services for management.
Study design
For the purposes of this survey, one evaluation unit (EU) 
consisted of one locality as that was the administrative 
unit that most closely met the WHO definition of 
a district for trachoma elimination purposes (a unit of 
health administration with a population of 100,000– 
250,000).10 All four EUs (population range: 123,725– 
267,593) were in the Darfur region of Sudan. 
Assuming a design effect of 2.63 and applying an 
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inflation factor of 1.2 to account for non-response, 
a sample of households that included 1164 children 
aged 1–9 years was required to have 95% confidence of 
estimating a prevalence of TF of 4% in 1–9-year-olds in 
each EU with an absolute precision of ±2%.11
A two-stage cluster sampling strategy was used for 
each survey, in-line with previous surveys in Darfur and 
WHO recommendations.6,11,12 The primary sampling 
unit was defined as a village. Villages were selected 
from a full list of villages in each EU using a probability- 
proportional-to-size method. Large villages were subdi-
vided into two or three sectors, which could each be 
independently selected. The secondary sampling unit 
was the household. The number of households to be 
surveyed per village was fixed at 30, based on the num-
ber of households a team could feasibly visit in a day. 
Households were selected through compact segment 
sampling; subsequent references to “clusters” in this 
paper refer to those compact segments. All residents 
aged ≥1 year from selected households were eligible for 
inclusion in the survey. According to records from the 
Darfur regional Expanded Programme on 
Immunization, a mean of 1.6 children aged 1–9 years 
was expected in each household. The target sample size 
would therefore be reached after surveying 25 clusters. 
The precision of the TT prevalence estimate was 
accepted as that generated by the sample of adults living 
in the households selected to meet the TF prevalence 
sample size; we acknowledge that, using a classical fre-
quentist statistical approach, this is imperfect for deter-
mining with confidence whether the elimination 
prevalence target for TT has been met.
Examination
Grading was undertaken by health-care professionals 
who had successfully completed the Tropical Data gra-
der training scheme before taking part in the surveys. 
This included completion of a classroom-based taught 
course on trachoma, achievement of a kappa score of 
≥0.7 in a classroom-based intergrader agreement (IGA) 
test of 50 photographs, which had previously been 
graded by international experts, and achievement of 
a kappa score of ≥0.7 against a Tropical Data-certified 
trachoma grader trainer in the assessment of 50 eyes of 
children of whom at least five had TF.13 Participants 
were examined for clinical signs of trachoma using 
2.5× binocular loupes and torchlight where necessary. 
Participants were graded for TF, TI and TT using the 
WHO simplified grading system with follicle size guides 
to support diagnosis of TF.2,14 In this survey, TT was 
graded when people were found to have one or more 
eyelashes touching the eyeball or evidence of recent 
epilation of in-turned eyelashes as per the original ver-
sion of the WHO simplified grading scheme published 
in 1987.2 Upper- and lower-eyelid trichiasis were not 
differentiated. Where a participant was identified with 
TT, they were additionally assessed for trachomatous 
scarring (TS), and asked questions about whether they 
had previously been offered management for their TT 
and whether they had accepted surgery or epilation.
Data were recorded by dedicated data recorders using 
the Secure Data Kit-based Tropical Data app (https:// 
www.tropicaldata.org). Data recorders were required to 
complete a training course on how to recognise different 
water, sanitation, and hygiene (WASH) service types 
and how to use the data collection app and then success-
fully pass an examination of their data entry fidelity. 
A full suite of quality assurance and quality control 
measures was implemented.15
Assessment of household water, sanitation, and 
hygiene infrastructure
Household heads nominated an individual to be asked 
questions adapted from the United Nations Childrens' 
Fund (UNICEF)/WHO Joint Monitoring Programme 
(JMP) for Water Supply and Sanitation WASH house-
hold questionnaire.12,13 The questionnaire assessed the 
proximity and status of water and sanitation facilities for 
each household. The questionnaire also assessed 
whether there was a handwash station within 15 m of 
the household latrine. (Handwash station questions 
were asked where there was an improved or unimproved 
latrine but not asked when there was no latrine.) Water 
source type, latrine type, and whether soap and water 
were available at the handwash station at the time of the 
visit were assessed by direct observation. Latrine type 
was categorised as either improved or unimproved, 
where improved refers to covered latrines in line with 
UNICEF/WHO JMP definitions.16
Data analysis
Disease prevalence was first calculated at cluster level 
and weighted according to the underlying population 
structure. Cluster-level TF prevalence was weighted in 
1-year age groups. Cluster-level TT prevalence was 
weighted in five-year age and gender groups. EU-level 
disease prevalence was defined as the mean age- (TF) or 
age- and gender-weighted (TT) cluster-level prevalence 
from each EU.
To assess whether there was a difference in the like-
lihood of having TF for those sampled after MDA com-
pared to those sampled before MDA, individual-level 
data were extracted from previous surveys in these 
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EUs.6 A mixed-effects regression model was run with TF 
as the dependent variable, and whether the individual 
was sampled before/after MDA, their age and their gen-
der included as fixed-effect independent variables. 
Cluster of residence was included as a random-effect 
variable. For the purposes of comparison of pre-MDA 
data to post-MDA data, data from post-MDA EUs were 
amalgamated to match pre-MDA EU boundaries. 
Separate models were run for the North Darfur EUs 
and the South Darfur EUs.
Mixed-effect regression was also used to determine 
whether there was any association between TF and indi-
vidual- and household-level variables. Cluster and 
household were evaluated as random-effect variables 
for all models (EU was not evaluated as a random effect 
variable as there were insufficient levels). Models with 
household of residence as a random-effects variable 
failed to converge suggesting overfitting. Therefore, 
cluster of residence was the only random-effect variable 
included in all models. The relative contribution of 
independent variables to overall model fit was calculated 
by likelihood ratio tests between models with and with-
out the variable of interest. Variables with strong evi-
dence of an association in univariable analysis (p < 0.05) 
were included in the multivariable model. The remain-
ing variables were added to the multivariable model in 
a stepwise manner to determine whether they improved 
the model fit and included if they did.
Analyses of the association between TT, age, and 
gender were not carried out due to the small number 
of TT cases identified.
Results
Study population
Data collection took place in December 2018 and 
January 2019. Table 1 summarises the number of people 
recorded as living in selected households and the num-
ber who did not take part, separated by reason for non- 
participation. A total of 12,080 people aged ≥1 year were 
enumerated across all EUs, of whom 11,248 (93%) were 
examined. The principal reason for non-participation 
was being absent at the time of the teams’ visit.
Prevalence of disease
Of 5,659 children aged 1–9 years examined, 197 cases of 
TF were identified. Only one case of TI was identified in 
1–9-year-olds across all four EUs. 125/197 (63%) cases 
of TF were bilateral. The adjusted prevalence of TF in 1– 
9-year-olds was <5% in each EU studied (range: 2.5– 
3.7%; Table 1). The post-MDA TF prevalence was lower 
than the pre-MDA TF prevalence (Figure 1) and indivi-
dual-level analyses suggested lower odds of having TF 
for children sampled after MDA compared to those 
sampled before MDA (North Darfur EUs adjusted 
Odds Ratio [aOR]: 0.28, 95% confidence interval [CI]: 
0.12–0.60, p = 0.002; South Darfur EUs aOR: 0.67, 95% 
CI: 0.44–1.02, p = 0.063). Compared to children aged 1– 
3 years, children aged 4–6 years and 7–9 years had lower 
odds of having TF (proportion of children with TF per 
age bracket in years: 1–3: 5%, 4–6: 3.5%, 7–9: 1.8%; 
aORs: 1–3 years versus 4–6 years: 0.62, 95% CI: 0.44– 
0.86; 1–3 years versus 7–9 years: 0.31, 95% CI: 0.20–0.47; 
p = 0.007; Supplementary Table 1). Children living in 
a household with ≥4 children aged 1–9 years had higher 
odds of having TF than children living in households 
Table 1. Proportion of the enumerated population who were enumerated and examined in four evaluation units (EUs) of Darfur region, 
Sudan, December 2018–January 2019.
State Locality EU ID
Pre-MDA prevalence6
Age group 













80929 9.3 0.6 1–9 1,266 13 0 0 1,253 (99) 620 (49)
≥15 1,351 174 1 0 1,176 (87) 796 (68)
Total (≥1) 2,817 188 1 0 2,628 (93) 1,526 (58)
Kalamindo 80930 1–9 1,357 21 1 1 1,334 (98) 695 (52)
≥15 1,268 166 1 1 1,100 (87) 765 (70)
Total (≥1) 2,872 190 2 2 2,678 (93) 1,603 (60)
South 
Darfur
Elsalam 80931 5.2 0.0 1–9 1,506 45 0 0 1,461 (97) 777 (53)
≥15 1,293 205 7 1 1,080 (84) 779 (72)
Total (≥1) 3,051 276 8 1 2,766 (91) 1,675 (61)
Belail 80932 1–9 1,629 18 0 0 1,611 (99) 799 (50)
≥15 1,341 137 3 0 1,201 (90) 902 (75)
Total (≥1) 3,340 161 3 0 3,176 (95) 1,927 (61)
MDA: mass drug administration; TF: trachomatous inflammation – follicular; TT: trachomatous trichiasis.
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with 1–3 children (aOR: 1.52, 95% CI: 1.12–2.06; 
p < .001; Supplementary Table 1).
In 4,557 ≥15-year-olds examined, 27 cases of TT were 
identified. Twenty-one (78%) of these cases had TS, and 
10 (37%) were affected bilaterally. Twenty-four (89%) of 
the individuals with TT were ≥50 years in age. Twenty 
(78%) reported never having previously been offered 
management for their TT and were therefore classed as 
“unknown to the health system.” The adjusted preva-
lence of TT unknown to the health system in ≥15-year- 
olds was <0.2% in each EU surveyed (range: 0.04– 
0.19%). EU-level prevalence data are summarised in 
Table 2 and visualised in Figure 2.
Water, sanitation and hygiene access
Water, sanitation and hygiene access was limited in all 
EUs. Overall, 39% of the households across all four EUs 
had access to an improved drinking water source within 
a 30-minute return journey of the house. The availability 
of improved latrines was particularly low, with 7% of 
households across all four EUs having an improved 
latrine (either shared or private). In general, fewer house-
holds visited in the post-MDA surveys had access to an 
improved latrine, to an improved washing water source, 
and to an improved washing water source within a 30- 
minute return journey of the house compared to the pre- 
MDA period (Figure 1). Only 14% of households had 
Figure 1. Difference in adjusted prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, proportion of households 
with an improved washing water source, proportion of households with a washing water source within a 30-minute return journey of 
the household and proportion of households with an improved latrine in four evaluation units of Sudan. Pre-antibiotic mass drug 
administration (MDA) survey data collected as part of the Global Trachoma Mapping Project, 2014 − 2015.6 Post-MDA data collected in 
December 2018–January 2019. There are two post-MDA estimates associated with each pre-MDA estimate due to the splitting of each 
pre-MDA evaluation unit (EU) into two EUs for post-MDA surveys. Prop. HH: Proportion of households
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Table 2. Prevalence of trachomatous inflammation – follicular and trachomatous trichiasis in four evaluation units (EUs) of Darfur 
region, Sudan, December 2018–January 2019.
State Locality















to the health 
system
Adjusted prevalence of TT¶ 
unknown to the health 
system, % (95% CI)
North Darfur Dar 
Elsalam
1,253 43 2.7 
(1.2–4.8)
1,176 3 3 3 0.08 
(0.00–0.17)
Kalamindo 1,334 47 2.5 
(1.4–3.8)
1,100 6 6 4 0.11 
(0.00–0.31)
South Darfur Elsalam 1,461 45 2.4 
(1.1–4.2)
1,080 3 4 3 0.04 
(0.00–0.09)
Belail 1,611 62 3.7 
(2.1–5.1)
1,201 9 14 10 0.19 
(0.03–0.44)
Total 5,659 197 - 4,557 21 27 20 -
TF: trachomatous inflammation—follicular; TT: trachomatous trichiasis. 
* In one or both eyes. 
¶In this survey, TT was graded when people were found to have one or more eyelashes touching the eyeball or evidence of recent epilation of in-turned lashes, 
as per the simplified grading scheme.2 Upper- and lower-lid trichiasis were not differentiated.
Figure 2. Prevalence of trachomatous inflammation – follicular (TF) in 1–9-year-olds and trachomatous trichiasis (TT) unknown to the 
health system in ≥15-year-olds in four evaluation units of Sudan. A single round of azithromycin mass drug administration (MDA) took 
place in these localities in 2017 and the surveys were completed in December 2018–January 2019. The boundaries and names shown 
and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the authors, or the 
institutions with which they are affiliated, concerning the legal status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries.
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a handwashing station within 15 m of their latrine at the 
time of the visit (Table 3).
Discussion
Excellent progress against trachoma has been made in 
these four EUs, with TF and TT prevalence in each EU 
below the respective targets for elimination of trachoma 
as a public health problem. The four EUs surveyed do 
not at present qualify for further antibiotic MDA for 
trachoma elimination purposes. This is a promising 
result after one round of antibiotic MDA, matching 
experience elsewhere.17–19 These Darfur EUs should be 
re-surveyed in December 2020–January 2021 following 
2 years of F and E interventions but without further 
MDA, to determine whether the low prevalence of TF 
measured here has been maintained. The low prevalence 
of TT in these EUs suggests that active case finding may 
not currently be necessary. However, the majority of TT 
cases identified were unknown to the health system, and 
a system for identifying and managing TT patients is one 
of the three criteria for validation of elimination,5 so 
these EUs should not be exempted from current nation-
wide efforts to build surgical capacity for TT.
Darfur residents are known to face significant chal-
lenges in accessing water, and improvement of WASH 
infrastructure coverage is a priority for Sudan’s govern-
ment and its partners.20 The WASH data collected during 
these surveys highlight the need for the environmental 
improvement component of the SAFE strategy. Access to 
WASH recorded in these EUs was generally in line with 
other contemporary estimates in Sudan. For example, the 
proportion of households with access to an improved 
drinking water source within a 30-minute round trip 
was comparable to recent national-level estimates from 
rural areas.16 The proportion of households with 
a private, improved latrine was also similar to national 
estimates.16 Moreover, compared to the results from the 
Global Trachoma Mapping Project baseline surveys in 
these localities,6 a lower proportion of the households 
surveyed after MDA had access to improved WASH 
facilities. Darfur has been subject to major armed conflict 
for a number of decades, and between 2010 and 2017, 
over 1.6 million people were internally displaced from 
Darfur due to the destruction of villages and shelters 
and ongoing violence.21 This has likely contributed to 
the reduction in access to improved WASH facilities, 
through direct destruction and greater use of limited 
existing WASH facilities.22
Given the association of trachoma with reduced access 
to water for WASH and the proximity of this population to 
other populations with high trachoma prevalence, a higher 



































































































































































































































































































































































































































































































































































































that if the observed decline in WASH access is not 
addressed and MDA treatments are discontinued, recru-
descence of trachoma may occur in the future.23 The strong 
association of greater sanitation coverage with lower TF 
prevalence in children has been demonstrated using data 
from standardised trachoma surveys undertaken in 13 
countries,24 and pilot studies in Ethiopia suggest the poten-
tial benefit of using soap when face-washing.25 However, 
trachoma prevalence is no doubt influenced by many com-
plex interacting factors, which were not evaluated by this 
survey methodology. For example, the migration of large 
numbers of untreated people into areas that have com-
pleted their designated rounds of MDA has been shown to 
increase the risk of reinfection with trachoma.26 
Considering the political instability of the Darfur region, 
it is highly likely that further migration events will occur, 
and thus continued trachoma surveillance of this area will 
be necessary if the prevalence of TF is to be maintained 
below the 5% threshold for elimination.
One key limitation of this study is the sample size used 
to estimate TT prevalence. We examined adults residing in 
houses selected to assess TF prevalence. Had these surveys 
been specifically designed to estimate TT prevalence, we 
would have expanded the number of clusters selected for 
each EU from 25 to 30 as recommended by the WHO.27 
We acknowledge that the confidence intervals around each 
TT prevalence estimate are relatively wide.
Nationwide trachoma control efforts continue in Sudan. 
In Darfur, neighbouring localities to those studied here had 
a higher TF prevalence during the most recent mapping 
exercise6; MDA is still ongoing in those districts, and 
impact surveys are anticipated in 2020–2021. Impact sur-
veys are also warranted in the Blue Nile region, where 
baseline surveys determined the prevalence of TF in 1– 
9-year-olds to be ≥10%.7 Finally, some localities in the 
Darfur region, for example, Buram and El Tina, remain 
unmapped. Baseline surveys are planned in those and other 
non-surveyed districts to identify whether interventions 
are required, although ongoing security concerns are likely 
to make this challenging. While many countries, including 
Sudan, have now missed the original elimination target of 
2020, Sudan has a good chance of eliminating trachoma as 
a public health problem within the next few years.
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